<i>In vitro</i> potency and pharmacokinetics of APG777, a novel anti-IL-13 mAb.

ABSTRACT:

Background

IL-13 plays a key role in the induction and perpetuation of type 2 immune responses associated with the development of atopic dermatitis and other chronic inflammatory diseases. mAbs targeting IL-13 have demonstrated efficacy in IL-13-driven diseases; however, current therapeutics require dosing every 2 to 4 weeks, resulting in significant injection burden for patients. APG777 is a humanized, IgG1 IL-13-targeting mAb that has been engineered to have an optimized pharmacokinetic profile, allowing for less frequent dosing.

Objective

We sought to investigate the in vitro potency and in vivo pharmacokinetics of APG777.

Methods

The affinity of APG777 was characterized using surface plasmon resonance; the half-maximal inhibitory concentration (IC

SUBMITTER: Zhu E 

PROVIDER: S-EPMC12419008 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature